Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular therapy for multiple myeloma.

G Martinelli1, P Tosi, E Ottaviani

  • 1Molecular Biology Unit, Institute of Hematology and Medical Oncology Seràgnoli, University of Bologna, via Massarenti 9, 40138 Bologna, Italy. gmartino@kaiser.alma.unibo.it

Haematologica
|September 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes.

Annals of hematology·2024
Same author

A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.

British journal of haematology·2023
Same author

Concurrent chromothripsis events in a case of TP53 depleted acute myeloid leukemia with myelodysplasia-related changes.

Cancer genetics·2019
Same author

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.

Leukemia·2015
Same author

Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.

The pharmacogenomics journal·2012
Same author

Gut microbiota as a candidate for lifespan extension: an ecological/evolutionary perspective targeted on living organisms as metaorganisms.

Biogerontology·2011

Novel molecular and cytogenetic advances offer new therapeutic strategies for multiple myeloma (MM). Targeting specific molecular pathways and the microenvironment shows promise for MM treatment, with clinical trials beginning.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multiple myeloma (MM) research is advancing with molecular and cytogenetic discoveries.
  • Novel therapeutic strategies are emerging for a potential cure for MM.

Purpose of the Study:

  • To identify novel, MM-specific molecular targets for drug development.
  • To explore drugs that selectively target neoplastic cells while sparing normal cells.
  • To investigate therapies that modify the bone marrow microenvironment.

Main Methods:

  • Evaluating drugs that induce apoptosis or growth arrest, such as proteasome inhibitors and lactacystin.
  • Assessing novel vascular endothelial growth factor (VEGF) inhibitors to block tumor-cell adhesion and proliferation.
  • Examining tyrosine kinase inhibitors (TKIs) for fibroblast growth factor receptor (FGFR) targeting in specific genetic MM cases.

Related Experiment Videos

  • Considering histone deacetylase (HDAC) inhibitors for MM with specific translocations.
  • Investigating Tumor Necrosis Factor Alpha-Related Apoptosis-Inducing Ligand (TRAIL) for its apoptotic effects.
  • Exploring farnesyltransferase inhibitors for Ras-mediated signaling pathways.

    • Main Results:

    • Preclinical studies for several novel therapeutic strategies have yielded encouraging results.
    • Drugs altering the microenvironment, including proteasome inhibitors and VEGF inhibitors, show promise.
    • FGFR inhibitors and HDAC inhibitors are potential options for specific MM genetic subtypes.
    • TRAIL demonstrates apoptosis-inducing capabilities in MM cells.
    • Farnesyltransferase inhibitors are being explored for Ras-pathway targeting.

    Conclusions:

    • Multiple promising therapeutic avenues are being explored for multiple myeloma.
    • Encouraging preclinical data support the initiation of clinical trials for these novel MM treatments.
    • Targeting specific molecular pathways and the tumor microenvironment represents a realistic approach for MM treatment advancement.